Skip to main content
SpringerLink
Log in

From metabolomics to proteomics: understanding the role of dopa decarboxylase in Parkinson’s disease. Scientific commentary on: “Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease”

  • Correspondence
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Abbreviations

BBB:

Blood–brain barrier

DDC:

Dopa decarboxylase

l-DOPA:

Levodopa (l-3,4-dihydroxyphenylalanine)

PAH:

Phenylalanine hydroxylase

PAL:

Phenylalanine ammonia-lyase

PD:

Parkinson’s disease

PLP:

Pyridoxal-5-phosphate

References

  1. Al Mughram MH, Ghatge MS, Kellogg GE, Safo MK (2022) Elucidating the interaction between pyridoxine 5′-phosphate oxidase and dopa decarboxylase: activation of B6-dependent enzyme. Int J Mol Sci 24(1):642. https://doi.org/10.3390/ijms24010642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bank RPD (2024) RCSB PDB-3RBF: crystal structure of human aromatic l-amino acid decarboxylase (AADC) in the apo form. https://www.rcsb.org/structure/3RBF. Accessed 24 Mar 2024

  3. Berry MD, Juorio AV, Li X-M, Boulton AA (1996) Aromaticl-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochem Res 21(9):1075–1087. https://doi.org/10.1007/BF02532418

    Article  CAS  PubMed  Google Scholar 

  4. Bjørke-Monsen A-L, Bjørk M-H, Storstein A, Ueland PM, Tysnes O-B (2022) Severe hyperhomocysteinemia in a patient with Parkinson disease. Clin Chem 68(3):396–401. https://doi.org/10.1093/clinchem/hvab262

    Article  PubMed  Google Scholar 

  5. Hadjiconstantinou M, Neff NH (2008) Enhancing aromatic l-amino acid decarboxylase activity: implications for l-DOPA treatment in Parkinson’s disease. CNS Neurosci Ther 14(4):340–351. https://doi.org/10.1111/j.1755-5949.2008.00058.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kalecký K, Bottiglieri T (2023) Targeted metabolomic analysis in Parkinson’s disease brain frontal cortex and putamen with relation to cognitive impairment. npj Parkinson’s Dis 9(1):Article 1. https://doi.org/10.1038/s41531-023-00531-y

    Article  CAS  Google Scholar 

  7. Rutledge J, Lehallier B, Zarifkar P, Losada PM, Shahid-Besanti M, Western D et al (2024) Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease. Acta Neuropathol 147(1):52. https://doi.org/10.1007/s00401-024-02706-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Schumacher-Schuh A, Bieger A, Borelli WV, Portley MK, Awad PS, Bandres-Ciga S (2021) Advances in proteomic and metabolomic profiling of neurodegenerative diseases. Front Neurol 12:792227. https://doi.org/10.3389/fneur.2021.792227

    Article  PubMed  Google Scholar 

  9. Shebl N, El-Jaafary S, Saeed AA, Elkafrawy P, El-Sayed A, Shamma S et al (2024) Metabolomic profiling reveals altered phenylalanine metabolism in Parkinson’s disease in an Egyptian cohort. Front Mol Biosci. https://doi.org/10.3389/fmolb.2024.1341950

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Institute of Global Health and Human Ecology, The American University in Cairo, Cairo, Egypt

    Nourhan Shebl & Mohamed Salama

  2. Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin 2, Ireland

    Mohamed Salama

  3. Faculty of Medicine, Mansoura University, El Mansûra, Egypt

    Mohamed Salama

Authors
  1. Nourhan Shebl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NS: Conceptualization, drafting the first version. MS: Conceptualization, reviewing the final version.

Corresponding author

Correspondence to Mohamed Salama.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethical approval and consent to participate

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shebl, N., Salama, M. From metabolomics to proteomics: understanding the role of dopa decarboxylase in Parkinson’s disease. Scientific commentary on: “Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease”. Acta Neuropathol 147, 88 (2024). https://doi.org/10.1007/s00401-024-02739-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00401-024-02739-5

Search

Navigation